Compare Capri Holdings Ltd (CPRI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs TG Therapeutics Inc — how do they compare? Capri Holdings Ltd trades at $14.98 (market cap $1.67B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 4.9× Capri Holdings Ltd's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and TG Therapeutics Inc for 16 Days on average.
| CPRI | TGTX | |
|---|---|---|
Market Cap | $1.67B | $8.16B |
Volume | 3,722,279 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $59.06 |
52-Week Low | $12.71 | $26.94 |
Typical Hold Time | 41 Days | 16 Days |
Enterprise Value | $2.95B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.95, up 3.53% today, with a bullish technical signal from moving averages and recent positive earnings beats. The stock shows a low P/S of 0.51 and strong gross margins above 62%, but faces challenges with a net loss of $1.18 billion in 2025 and declining revenue trends. Recent news highlights management's focus on brand revitalization and second-half growth expectations for Michael Kors and Jimmy Choo.
The outlook is mixed: valuation appears attractive and earnings momentum is positive, but sustained revenue growth and margin recovery are critical for upside. Key risks include execution on the Michael Kors turnaround, competitive pressures, and macroeconomic sensitivity. The consensus price target of $20.57 suggests potential appreciation if operational improvements materialize.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
